Mahana Therapeutics Funding: $81M Raised, Series B (2021)
Mahana Therapeutics has raised $81M in total funding. Latest round: Series B. Backed by JAZZ Venture Partners, Gurnet Point Capital, Main Street Advisors.
Mahana Therapeutics funding overview
Mahana Therapeutics has raised $81M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in August 2021. The round record for Mahana Therapeutics runs through 2021; nothing later has been disclosed. Investors on record include JAZZ Venture Partners, Gurnet Point Capital, Main Street Advisors, KKCG, Lux Capital. 5 distinct backers are named across the disclosed rounds.
Mahana Therapeutics at a glance
Total raised
$81M
Latest round
Series B
Latest round date
August 2021
Notable investors
JAZZ Venture Partners, Gurnet Point Capital, Main Street Advisors, KKCG, Lux Capital
Frequently asked about Mahana Therapeutics funding
How much has Mahana Therapeutics raised?
Mahana Therapeutics has raised $81M in total disclosed funding across the rounds on record.
Who has invested in Mahana Therapeutics?
JAZZ Venture Partners, Gurnet Point Capital, Main Street Advisors, KKCG, Lux Capital are named among the investors backing Mahana Therapeutics.
What was the latest Mahana Therapeutics funding round?
The most recent disclosed round is a Series B, announced in August 2021.
Where is Mahana Therapeutics based?
No headquarters location is disclosed for Mahana Therapeutics.
When did Mahana Therapeutics last raise?
The last disclosed Mahana Therapeutics round closed in August 2021 at Series B.
Round data for Mahana Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies and backer lists below.
